StockData
Citius Oncology, Inc. logo

Citius Oncology, Inc. (CTOR) stock

CTORNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30
$0.56+0.01 (+1.79%)

Close on Nov 18, 2026Market cap $51.83MP/E –Yield –

Citius Oncology net income

Net income is the profit left for shareholders after every expense, interest and tax.

Citius Oncology's net income for the twelve months ending Jun 30, 2026 was -$46.06M. For fiscal 2025 it was -$24.76M, down 6602.3% from the year before.

Annual net income

PeriodPeriod endValueChange
FY2025Sep 30, 2025-$24.76M-6602.3%
FY2022Dec 31, 2022$380.81K–

Quarterly net income

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026-$8.92M–
Q2 FY2026CQ1 2026Mar 31, 2026-$26.61M–
Q1 FY2026CQ4 2025Dec 31, 2025-$5.53M–
Q4 FY2025CQ3 2025Sep 30, 2025-$5.00M–
Q3 FY2025CQ2 2025Jun 30, 2025-$5.37M–
Q2 FY2025CQ1 2025Mar 31, 2025-$7.74M–
Q1 FY2025CQ4 2024Dec 31, 2024-$6.66M–
Q2 FY2021CQ2 2021Jun 30, 2021-$724–

More Citius Oncology figures

See a number that looks wrong?